Stay up to date on the innovative research in cell and gene therapy and the implications for disease treatment. Ray Roth reviews the benefits and risks of these therapies, the financing and partnerships occurring, and payer issues and tactics for supporting the reimbursement for cell and gene therapies.
Rare and orphan drug therapies have had exponential growth in the last decade. Kellie Rademacher explores their costs and impact to payers and the overarching healthcare systems, as well as value-based agreements that are being explored to pay for these therapies.
What role do specialty pharmacies have in cell and gene therapies for payers, providers, manufacturers, and patients? Erin Lopata highlights the SP’s roles in partnership coordination between payers and manufacturers, the leveraging of data to support arrangements, and the focus on patient-care coordination and financial support to improve patient outcomes.
Janet Serluco addresses trends impacting access in cancer care and the innovative payment models being considered to pay for these high-cost therapies, as well as the need to focus on value of therapies in the oncology and gene therapy space to support access and reimbursement.
